References
- Nappi RE, Cucinella L, Martella S, et al. Female sexual dysfunction (FSD): prevalence and impact on quality of life (QoL). Maturitas. 2016;94:87–91.
- Nappi RE, Cucinella L. Advances in pharmacotherapy for treating female sexual dysfunction. Expert Opin Pharmacother. 2015;16:875–887.
- Sobecki JN, Curlin FA, Rasinski KA, et al. What we don’t talk about when we don’t talk about sex: results of a national survey of U.S. obstetrician/gynecologists. J Sex Med. 2012;9:1285–1294.
- Kingsberg SA, Althof S, Simon JA, et al. Female sexual dysfunction-medical and psychological treatments, committee 14. J Sex Med. 2017;14:1463–1491.
- Palacios S, Castelo-Branco C, Currie H, et al. Update on management of genitourinary syndrome of menopause: a practical guide. Maturitas. 2015;82:308–313.
- Bruyniks N, Nappi RE, Castelo-Branco C, et al. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric. 2016;19:60–65.
- Labrie F, Bélanger A, Pelletier G, et al. Science of intracrinology in postmenopausal women. Menopause. 2017;24:702–712.
- Clayton AH, Goldstein I, Kim NN, et al. The international society for the study of women’s sexual health process of care for management of hypoactive sexual desire disorder in women. Mayo Clin Proc. 2018;93:467–487.
- Simon JA, Davis SR, Althof SE, et al. Sexual well-being after menopause: an international menopause society white paper. Climacteric. 2018;21:415–427.
- Nappi RE. Why are there no FDA-approved treatments for female sexual dysfunction? Expert Opin Pharmacother. 2015;16:1735–1738.
- Nappi RE, Cucinella L, Tiranini L, et al. Has flibanserin revolutionized the treatment of hypoactive sexual desire disorder or is there still room for more effective therapeutics? Expert Opin Pharmacother. 2018;19:421–423.
- Miller MK, Smith JR, Norman JJ, et al. Expert opinion on existing and developing drugs to treat female sexual dysfunction. Expert Opin Emerg Drugs. 2018;23:223–230.
- Weinberger JM, Houman J, Caron AT, et al. Female sexual dysfunction and the placebo effect: a meta-analysis. Obstet Gynecol. 2018;132:453–458.
- Pyke RE, Clayton AH. Effect size in efficacy trials of women with decreased sexual desire. Sex Med Rev. 2018;6:358–366.
- Clayton HA, Kingsberg S, Simon J, et al. 014 the investigational drug bremelanotide for Hypoactive Sexual Desire Disorder (HSDD): efficacy analyses from the RECONNECT studies. J Sex Med. 2018;15(Suppl 1):S7–S8.